Conference Coverage: ASCO 2022 – Focus on Breast Cancer

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making coming out of the ASCO 2022 conference.

June 14, 2022

FACULTY CHAIR

Adam Brufsky, MD, PhD, FACP

Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA

FACULTY MEMBERS

Giuseppe Curigliano, MD, PhD
University of Milano, Italy

Mark D. Pegram, MD
Stanford Cancer Institute, Stanford, CA, USA

Peter A. Kaufman, MD
The University of Vermont Medical Center, Burlington, VT, USA

Joseph Gligorov, MD, PhD
APHP Tenon, Paris, France

Guy H. Jerusalem, MD, PhD
University of Liège/CHU de Liège, Belgium

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Updates on Neoadjuvant Therapies for Breast Cancer
  • CDK4/6 Inhibitors in the Treatment of HR+, HER2– Breast Cancer
  • Novel Therapeutic Approaches for HR+, HER2– Breast Cancer
  • Evolving Treatments for HER2+, HER2–, and HER2-Low Breast Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.